New England Venture Activity Rebounds Slightly in Q2—Region’s Top 10 Deals List
Ryan McBride7/21/09Leave a Comment
(Page 2 of 2)
New England’s Top 10 Venture Deals—Q2 2009*
Powerspan (Portsmouth, NH) — $54 million
(Investors: AllianceBernstein, Angeleno Group, Beacon Group, Calvert Social Venture Partners, FirstEnergy Corporation, NGEN Partners, and RockPort Capital Partners)
ConforMIS (Burlington, MA) — $50 million
(Investors: Aeris Capital, SBG Sachsen-Anhalt, and Thorner Ventures)
Aileron Therapeutics (Cambridge, MA) — $40.15 million
(Investors: Apple Tree Partners, Excel Venture Management, Lilly Ventures, Novartis Venture Fund, Roche Venture Fund, and SR One)
Synageva BioPharma (Waltham, MA) — $33 million
(Investors: Baker Brothers Investments, Hunt BioVentures, Tullis Health Investors, and Yasuda Enterprise Development)
Tokai Pharmaceuticals (Cambridge) — $22 million
(Investors: Apple Tree Partners and Novartis Venture Fund)
Interlace Medical (Framingham, MA) — $20.5 million
(Investors: Aperture Venture Partners, Baird Venture Partners, Hambrecht & Quist Capital Management, HLM Venture Partners, New Leaf Venture Partners, and Spray Venture Partners)
Concert Pharmaceuticals (Lexington, MA) — $16.3 million
(Investor: GlaxoSmithKline)
I-Therapeutix (Waltham) — $15 million
(Investors: Polaris Venture Partners, SV Life Sciences, and Versant Ventures)
Demandware (Woburn, MA) — $15 million
(Investors: General Catalyst Partners and North Bridge Venture Partners)
Elixir Pharmaceuticals (Cambridge) — $12 million
(Investors: ARCH Venture Partners, MPM Capital, Omega Fund, Oxford Bioscience Partners, and Physic Ventures)
